"The voice for cancer physicians and their patients in Massachusetts."

FDA approves brigatinib (Alunbrig) for ALK-positive metastatic NSCLC

02 Jun 2020 2:40 PM | Anonymous

The U.S. Food and Drug Administration approved brigatinib (ALUNBRIG, Takeda) for adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. Read full press release.

© Copyright.  All rights reserved. 

Massachusetts Society of Clinical Oncologists

P.O. Box 549154, Waltham, MA, 02454
Tel: 781.434.7329 | Fax: 781.464.4896 | email: msco@mms.org

Powered by Wild Apricot Membership Software